[Biojava-l] Highly Regarded Industry Experts to Deliver Keynote Presentations at TIDES(R)

[support at biotaq.com]

********************************************************
to unsubscribe, simply reply to this email, thanks.
********************************************************

TIDES 2003 TO ATTRACT OVER 400 PEOPLE
HIGHLY REGARDED INDUSTRY EXPERTS TO DELIVER KEYNOTE PRESENTATIONS

Westborough, MA, April 1, 2003 – In continuing with its many years of
tradition, TIDES® 2003 will again attract over 400 people when it convenes
from April 28 - May 1, 2003 in Las Vegas, NV. The main event, which
includes IBC's 7th International Oligonucleotide Technology Conference and
the 6th International Peptide Technology Conference, features the
following keynote presentations from acknowledged industry experts:

Prospects for the Oligonucleotide-Based Drugs in Development
Professor C.A. Stein, M.D., Ph.D., Professor of Medicine, Urology and
Molecular Pharmacology,
Albert Einstein College of Medicine
At the present time, two phosphorothioate antisense oligonucleotides are
in Phase III clinical trials. Genasesne is being evaluated in advanced
melanoma, myeloma, and chronic lymphocytic leukemia, with and without (in
the case of CLL) cytotoxic chemotherapy. Affinitak (a.k.a. Isis 3521) is
being evaluated by Isis in collaboration with Eli Lilly in advanced
non-small cell lung cancer, in combination with cytotoxic chemotherapy.
Data analysis is anticipated by the second quarter of '03. These critical
trials, and important mechanistic questions that they raise, will be
discussed.

Drug Development Case History: Exenatide (AC2993; Synthetic Exendin-4)
Andrew A. Young, M.D., Ph.D., Vice President and Senior Research Fellow,
Amylin Pharmaceuticals Inc.
Exenatide (synthetic exendin-4), a 39 amino acid peptide currently being
explored as an antidiabetic therapy in patients with type 2 diabetes,
exhibits many of the actions of the human hormone, glucagon-like peptide-1
(GLP-1). But some key attributes not shared with GLP-1 have promoted its
success as a drug development candidate. Plasma stability and high in vivo
potency have resulted in multiple favorable pharmaceutical properties,
including for example, the enablement of non-injectable and/or long-acting
formulations.

Other topics in the 2003 TIDES® agenda include updates on therapeutics in
late-stage clinical development, formulation and delivery, large-scale
synthesis and purification for peptide and oligonucleotide-based
therapeutics, high-throughput chemistry for research applications,
considerations for diagnostic applications, PLUS a new session on
analytical characterization of oligo- and peptide-based therapeutics.
Interactive focus groups, a new Start-Up showcase and more will also take
place.

ATTENTION CALENDAR EDITORS!
For more information on attending TIDES® 2003 Oligonucleotide and Peptide
Technology Conferences from April 28 - May 1, 2003 at the Mandalay Bay
Resort & Casino in Las Vegas, NV, visit
http://www.lifesciencesinfo.com/TIDES; call 508-616-5550 or e-mail
mailto:aallen at ibcusa.com

ABOUT IBC LIFE SCIENCES
IBC Life Sciences, a part of the Informa Group plc - the leading provider
of scientific, technological and business information to the global life
science community - offers quality learning and networking events, and has
established industry-leading North American and European events in three
primary market sectors: Drug Discovery, Microtechnology, and
Biopharmaceutical Production. Other members of the Group include: D&MD,
publisher of D&MD Newsletter and Bioprocess News, in addition to its line
of D&MD Reports, Executive Briefings, Focus Reports, and How-To Guides;
Eaton Publishing Co., publisher of BioTechniques(R), the leading
peer-reviewed international journal of laboratory technology for
bioresearch; and BioProcess International(TM), devoted to the development,
scale-up, and manufacture of biotherapeutics.  Learn more at
www.lifesciencesinfo.com.
********************************************************
This segmented email list tends to serve the people who are
interested in news and product info in Peptide sector. To
unsubscribe, simply reply to this email.

To distribute your releases to this list, contact sales at biotaq.com.

To order market report "Cancer Immunotherapy Beyond Monoclonals"
from Biotaq.com at:

http://www.biotaq.com/onsale/biotaqreports.htm

BIOTAQ.COM's email Newswire service is focused exclusively on biotech
industry. Edit or change your interest category selections at:

https://www.biotaq.com/interests.htm
**************************************************************************
**